China's Shenzhen Kangtai Biological Products Co., Ltd. (BioKangtai) held a signing ceremony online with Chile's Advanced Medical Systems And Investments S.A., the University of Chile, and other institutions on Monday, May 24.

Several parties reached agreements on Phase III clinical trials and product procurement for BioKangtai's inactivated COVID-19 vaccine in Chile in the virtual ceremony.

BioKangtai announced on May 14 that its COVID-19 vaccine was approved for emergency use in China.

At present, BioKangtai has started Phase III clinical trials of the COVID-19 vaccine in many countries worldwide.